Gilead CEO Becomes Billionaire on $84,000 Hepatitis Drug

John C. Martin, the chief executive officer of Gilead Sciences Inc., has become a billionaire on the prospects of a powerful new hepatitis C drug that’s attracting scrutiny from payers and activists over its $1,000 per pill price tag.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.